Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 19, 2018 - Issue 1-2
Submit an article Journal homepage
7,275
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance

Lisa MengCytokinetics, Inc, Cupertino, CA, USA, Correspondence[email protected]
,
Amy BianCytokinetics, Inc, South San Francisco, CA, USA, and
,
Scott JordanCytokinetics, Inc, South San Francisco, CA, USA, and
,
Andrew WolffCytokinetics, Inc, South San Francisco, CA, USA, and
,
Jeremy M. ShefnerDepartment of Neurology, Barrow Neurological Institute, Saint Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
&
Jinsy AndrewsCytokinetics, Inc, South San Francisco, CA, USA, and
Pages 134-142 | Received 08 Mar 2017, Accepted 23 Jul 2017, Published online: 11 Sep 2017

Figures & data

Table 1. Disability milestones as defined by the Healthcare Common Procedure Coding System (Citation22).

Figure 1. Monthly costs to diagnosis for the pure Medicare population. Monthly costs were calculated as average monthly costs per patient. Index month (black square); 1–8 months before (grey diamonds); 9 + months before (black triangles).

Figure 1. Monthly costs to diagnosis for the pure Medicare population. Monthly costs were calculated as average monthly costs per patient. Index month (black square); 1–8 months before (grey diamonds); 9 + months before (black triangles).

Figure 2. Total allowed costs after index date as a measure of survival time in a pure Medicare population.

Figure 2. Total allowed costs after index date as a measure of survival time in a pure Medicare population.

Table 2. Monthly costs per patient associated with ALS in the pure Medicare populationTable Footnote*.

Figure 3. Monthly costs to diagnosis for the pure commercial population. Monthly costs were calculated as average monthly costs per patient. Index month (black square); 1–8 months before (grey diamonds); 9 + months before (black triangles).

Figure 3. Monthly costs to diagnosis for the pure commercial population. Monthly costs were calculated as average monthly costs per patient. Index month (black square); 1–8 months before (grey diamonds); 9 + months before (black triangles).

Table 3. Monthly costs per patient associated with ALS in the commercial populationTable Footnote*.

Figure 4. ALS costs during insurance transition. The light grey bars represent costs between coverage stages – for example, after diagnosis and until Medicare eligibility, or after getting eligibility.

Figure 4. ALS costs during insurance transition. The light grey bars represent costs between coverage stages – for example, after diagnosis and until Medicare eligibility, or after getting eligibility.

Figure 5. ALS costs before and after Medicare eligibility.

Figure 5. ALS costs before and after Medicare eligibility.

Table 4. Total costs from index date to disability milestones in pure Medicare casesTable Footnote*.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.